145 related articles for article (PubMed ID: 38353798)
41. Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.
Gugliemetti G; Sukhu R; Conca Baenas MA; Meeks J; Sjoberg DD; Eastham JA; Scardino PT; Touijer K
Actas Urol Esp; 2016 Sep; 40(7):434-9. PubMed ID: 27184342
[TBL] [Abstract][Full Text] [Related]
42. [Extended sentinel lymph node dissection in radical prostatectomy for prostate cancer: a study in the Kiel risk population].
Hautmann S; Beitz S; Naumann M; Lützen U; Seif C; Stübinger SH; van der Horst C; Braun PM; Leuschner I; Henze E; Jünemann KP
Urologe A; 2008 Mar; 47(3):299-303. PubMed ID: 18273596
[TBL] [Abstract][Full Text] [Related]
43. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
44. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
Dekalo S; Kuten J; Mintz I; Fahoum I; Gitstein G; Keizman D; Sarid D; Matzkin H; Mabjeesh NJ; Beri A; Even-Sapir E; Yossepowitch O; Mano R
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):910-916. PubMed ID: 33790418
[TBL] [Abstract][Full Text] [Related]
45. Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy.
Zareba P; Eastham J; Scardino PT; Touijer K
J Urol; 2017 Nov; 198(5):1077-1084. PubMed ID: 28625507
[TBL] [Abstract][Full Text] [Related]
46. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram.
Meijer HJ; Debats OA; Roach M; Span PN; Witjes JA; Kaanders JH; van Lin EN; Barentsz JO
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1186-91. PubMed ID: 22520482
[TBL] [Abstract][Full Text] [Related]
47. Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?
Sivaraman A; Benfante N; Touijer K; Coleman J; Scardino P; Laudone V; Eastham J
Investig Clin Urol; 2018 Mar; 59(2):83-90. PubMed ID: 29520383
[TBL] [Abstract][Full Text] [Related]
48. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
49. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors in lymph node-positive prostate cancer.
Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
[TBL] [Abstract][Full Text] [Related]
51. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy.
Lunger L; Retz M; Bandur M; Souchay M; Vitzthum E; Jäger M; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Koll F; Gschwend JE; Nawroth R; Heck MM
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):362-369. PubMed ID: 32978525
[TBL] [Abstract][Full Text] [Related]
52. [Impact of Gleason score on biochemical recurrence free survival after radical prostatectomy with positive surgical margins].
Roux V; Eyraud R; Brureau L; Gourtaud G; Senechal C; Fofana M; Blanchet P
Prog Urol; 2017; 27(8-9):467-473. PubMed ID: 28576421
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
[TBL] [Abstract][Full Text] [Related]
54. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
[TBL] [Abstract][Full Text] [Related]
55. Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: ten years of follow-up.
Rouanne M; Rode J; Campeggi A; Allory Y; Vordos D; Hoznek A; Abbou CC; De La Taille A; Salomon L
Scand J Urol; 2014 Apr; 48(2):131-7. PubMed ID: 23883410
[TBL] [Abstract][Full Text] [Related]
56. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
57. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
[TBL] [Abstract][Full Text] [Related]
58. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
Palapattu GS; Allaf ME; Trock BJ; Epstein JI; Walsh PC
J Urol; 2004 Nov; 172(5 Pt 1):1860-4. PubMed ID: 15540739
[TBL] [Abstract][Full Text] [Related]
59. Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
Izol V; Ok F; Aslan G; Akdogan B; Sozen S; Ozden E; Celik O; Muezzinoglu T; Turkeri L; Akdogan N; Baltaci S
Prostate; 2022 May; 82(7):763-771. PubMed ID: 35188993
[TBL] [Abstract][Full Text] [Related]
60. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy.
May F; Hartung R; Breul J
BJU Int; 2001 Nov; 88(7):702-7. PubMed ID: 11890240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
